PT-141 expands our toolkit, giving hope to men who previously had limited options
Medicare Part D enrollees may be able to get the pill for $50 per month as soon as July 1, according to Lilly, though Medicare has not yet announced coverage
Semaglutide (Wegovy) is FDA-approved for chronic weight management (with criteria) and has strong clinical trial evidence for meaningful average weight loss when paired with lifestyle support
Patients who switched to phentermine after losing at least 20 pounds while on the GLP-1 medication were most likely to regain weight one year after discontinuing their GLP-1 medication, with more than half regaining some or all their weight
Hair loss is a definitive side effect, but current evidence suggests this is something to watch out for
Heart Rate Increase: Both adults and pediatric patients experienced mean increases in resting heart rate of 1 to 4 beats per minute (bpm) in semaglutide patients compared to placebo in clinical trials